Evaluation of ifosfamide salvage therapy for metastatic canine osteosarcoma

Abstract

A retrospective study was performed to assess toxicity and response rate of ifosfamide salvage treatment for dogs diagnosed with metastatic osteosarcoma (OSA). Dogs diagnosed with OSA and previously treated with standard chemotherapy were included in the study. Nineteen dogs met the inclusion criteria, and 17 dogs were evaluable for response. Ifosfamide doses ranged from 375 to 425mgm-2 (median dose 375mgm-2), with a median of two doses administered per dog (range 1-7 doses). The overall response to ifosfamide was 11.8% [complete response (CR)=1/17, partial response (PR)=1/17, stable disease (SD)=2/17, progressive disease (PD)=13/17]. Two dogs were hospitalized due to ifosfamide toxicosis. The median survival duration from the first dose of ifosfamide to death was 95days. Ifosfamide was well tolerated, but minor anti-tumour activity was observed.